ImmuCell Corporation
ICCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | -0.05 | -0.01 | 8.41 |
| FCF Yield | -0.26% | -16.76% | -11.68% | -2.72% |
| EV / EBITDA | 48.14 | -21.93 | 154.10 | 22.39 |
| Quality | ||||
| ROIC | -3.87% | -13.80% | -5.38% | -5.81% |
| Gross Margin | 29.97% | 25.16% | 41.19% | 44.98% |
| Cash Conversion Ratio | -0.17 | 0.81 | 0.62 | -12.19 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.58% | -3.17% | 6.57% | 11.93% |
| Free Cash Flow Growth | 98.36% | -18.98% | -233.59% | 39.99% |
| Safety | ||||
| Net Debt / EBITDA | 10.22 | -6.27 | 19.11 | 0.03 |
| Interest Coverage | -2.88 | 0.00 | -6.60 | -7.01 |
| Efficiency | ||||
| Inventory Turnover | 2.61 | 1.67 | 1.81 | 3.43 |
| Cash Conversion Cycle | 173.88 | 238.94 | 210.85 | 132.45 |